Near-infrared two-region iridium complex with aggregation-induced emission property as well as preparation method and application of near-infrared two-region iridium complex

By designing D-A-D type near-infrared second-zone iridium complex, the problem of insufficient maximum emission wavelength of the aggregate-induced luminescent molecules in the prior art is solved, and the efficient emission of molecules in the near-infrared second-zone and multimodal photodiagnosis and treatment application is achieved.

CN118930585AActive Publication Date: 2024-11-12SHENZHEN UNIV

Patent Information

Application Number
CN202410982089.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

The maximum emission wavelength of existing near-infrared two-zone aggregation-induced luminescent molecules is difficult to exceed 1000nm, which limits its development and application in multifunctional aggregation-induced luminescent diagnostic and therapeutic agents.

Method used

A near-infrared two-zone iridium complex with a D-A-D type structure was designed, using dipyrido[3,2-a:2',3'-c][1,2,5]thiadiazolo[3, 4-i]Phenazine as the acceptor and triphenylamine as the donor, combined with iridium ion coordination, inhibits aggregation through propeller-type structure and thiophene π-bridge, achieving reduced molecular energy gap and redshift absorption and emission.

Benefits of technology

It realizes efficient emission of molecules in the second region of near infrared, enhances fluorescence, reactive oxygen generation and photothermal conversion capabilities, making them suitable for multimodal photodiagnostic agents for cancer diagnosis and treatment and imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930585A_ABST
    Figure CN118930585A_ABST
Patent Text Reader

Abstract

The invention discloses a near-infrared two-region iridium complex with aggregation-induced emission property and a preparation method and application thereof, the structural formula of the near-infrared two-region iridium complex is as shown in # imgabs0 #, R1 is selected from one of S and Se, R2 and R3 are independently selected from one of H and # imgabs1 #, and R4 is selected from one of H and F. According to the invention, a D-A-D type NN ligand taking bipyridino [3, 2-a: 2 ', 3'-c] [1, 2, 5] thiadiazolo [3, 4-i] phenazine as an acceptor (A) and triphenylamine as a donor (D) and an iridium complex thereof are designed, and a large conjugate rigid acceptor and a D-A-D structure can ensure that a molecule has a relatively low energy gap, so that the molecule has near-infrared two-region (NIR-II) emission; propeller type triphenylamine and ortho-alkyl substituted thiophene pi-bridge can effectively inhibit molecular aggregation, so that the polymer has the aggregation-induced emission property. Meanwhile, after coordination of the electron-withdrawing iridium ions, the electron-withdrawing capability of the acceptor and the absorption and emission red shift of the whole molecule are further improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of fluorescent molecular probes, and in particular to a near-infrared second-zone iridium complex with aggregation-induced luminescence properties, and a preparation method and application thereof. Background Art

[0002] Cancer has become a persistent public health challenge that the world is currently facing, causing huge burdens and economic losses to patients, families and society. Compared with the traditional model of separate diagnosis and treatment, optical diagnosis and treatment has the advantages of high diagnosis and treatment efficiency, non-invasiveness, low toxicity and side effects, and strong spatiotemporal selectivity. Photothermal-photodynamic synergistic therapy guided by fluorescence-photoacoustic-photothermal imaging is a new type of multimodal optical diagnosis and treatment that has emerged in recent years. Its advantage is that it can make up for the shortcomings of a single imaging and treatment method by combining the advantages of multiple imaging and treatment methods, thereby maximizing the efficiency of treatment diagnosis.

[0003] The property of significantly enhanced luminescence in the aggregated state of aggregation-induced emission molecules makes it a powerful tool to overcome the aggregation fluorescence quenching problem that is common in traditional luminescent molecules. The structure of aggregation-induced emission molecules has a propeller-like conformation, a large number of rotors and modifiable groups, which can balance and control the energy dissipation pathway and ratio of aggregation-induced emission molecules from the excited state to the ground state. It is an ideal template for constructing molecules with near-infrared region II (NIR-II) emission, photothermal and photodynamic properties.

[0004] At present, the construction of NIR-II molecules with aggregation-induced emission characteristics follows the design principle of "skeleton distortion and peripheral rotors". The mainstream molecular configuration is donor-acceptor-donor type, in which the donor is mainly concentrated on triphenylamine and its derivatives, and the acceptor is mainly limited to bisbenzothiadiazole (BBT) and thiadiazolylquinoxaline (PTQ). Moreover, these two acceptors are insufficient to meet the long-term development and wide application of multifunctional aggregation-induced emission photodiagnostic agents due to their stability problems and the defects of insufficient red absorption and emission (the maximum emission wavelength is difficult to exceed 1000nm).

[0005] Therefore, the prior art still needs to be improved and developed. Summary of the invention

[0006] In view of the above-mentioned deficiencies in the prior art, the present invention provides a near-infrared zone II iridium complex with aggregation-induced emission properties and a preparation method and application thereof, aiming to solve the problem that the maximum emission wavelength of existing near-infrared zone II aggregation-induced emission molecules is difficult to exceed 1000nm, and enrich the existing near-infrared zone II aggregation-induced emission molecular material construction strategy.

[0007] The technical solution adopted by the present invention to solve the above technical problems is as follows:

[0008] In a first aspect of the present invention, a near-infrared second-region iridium complex having aggregation-induced emission properties is provided, and its structural formula is as follows:

[0009]

[0010] Wherein, R1 is selected from one of S and Se, R2 and R3 are independently selected from H and R4 is selected from one of H and F.

[0011] The second aspect of the present invention provides a method for preparing the near-infrared second-region iridium complex having aggregation-induced emission properties as described above, the preparation method comprising the following steps:

[0012] Under a protective atmosphere, formula I and formula II are added to a solvent, and a first stirring treatment is performed, and then an ion exchanger is added, and a second stirring treatment is performed to obtain a near-infrared second-zone iridium complex having aggregation-induced emission properties and a structural formula as shown in formula III;

[0013] The above reaction route is as follows:

[0014]

[0015] Preferably, the molar ratio of Formula I to Formula II is (1.5-2.5):1.

[0016] Preferably, the solvent is a mixed solvent including dichloromethane and methanol.

[0017] Preferably, the molar ratio of the ion exchanger to formula I is (1-2):1.

[0018] Preferably, the ion exchanger is potassium hexafluorophosphate or potassium tetrafluoroborate.

[0019] Preferably, the first stirring treatment is specifically: stirring at 40-60° C. for 12-18 hours in dark conditions; and the second stirring treatment is specifically: stirring at room temperature for 4-6 hours.

[0020] Preferably, after the second stirring process, the method further comprises the following steps:

[0021] After the mixed solvent is evaporated, a purification treatment is performed to obtain the near-infrared second-zone iridium complex with aggregation-induced luminescence properties.

[0022] The third aspect of the present application provides the use of the above-mentioned near-infrared second-zone iridium complex with aggregation-induced emission properties in the preparation of multimodal integrated diagnosis and treatment reagents.

[0023] Preferably, the multimodal integrated diagnosis and treatment reagent is used to treat cancer.

[0024] Beneficial effects:

[0025] The invention discloses a near-infrared II region iridium complex with aggregation-induced emission properties, a preparation method and an application thereof. The invention designs a DAD-type N^N ligand with dipyrido[3,2-a:2',3'-c][1,2,5]thiadiazo[3,4-i]phenazine as an acceptor (A) and triphenylamine as a donor (D), and an iridium complex thereof. The large conjugated rigid acceptor and the DAD structure can ensure that the molecule has a lower energy gap, so that it has near-infrared II region (NIR-II) emission. The propeller-type triphenylamine and the ortho-alkyl-substituted thiophene π-bridge can effectively inhibit the aggregation of the molecule, so that it has aggregation-induced emission properties.

[0026] At the same time, the electron-withdrawing iridium ion further improves the electron-withdrawing ability of the receptor after coordination, and the absorption and emission of the entire molecule are red-shifted. The near-infrared second-zone iridium complex with aggregation-induced luminescence properties provided by the present invention has good fluorescence, reactive oxygen species (ROS) generation and photothermal conversion capabilities, making it a multimodal photodiagnostic agent that takes into account both imaging and treatment, and can be used for integrated research on multimodal diagnosis and treatment of cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 It is a synthetic route for preparing a near-infrared second-region iridium complex having aggregation-induced emission properties according to an embodiment of the present invention;

[0028] Figure 2 This is the nuclear magnetic resonance hydrogen spectrum of the near-infrared second-zone iridium complex ppy-oiC8-N^N with aggregation-induced emission properties prepared in Example 1 of the present invention in deuterated chloroform;

[0029] Figure 3 This is the carbon nuclear magnetic resonance spectrum of the near-infrared second-zone iridium complex ppy-oiC8-N^N with aggregation-induced emission properties prepared in Example 1 of the present invention in deuterated chloroform;

[0030] Figure 4 This is the nuclear magnetic resonance hydrogen spectrum of the near-infrared second-zone iridium complex 2Fppy-oiC8-N^N with aggregation-induced emission properties prepared in Example 2 of the present invention in deuterated chloroform;

[0031] Figure 5 This is the nuclear magnetic resonance fluorine spectrum of the near-infrared second-zone iridium complex 2Fppy-oiC8-N^N with aggregation-induced emission properties prepared in Example 2 of the present invention in deuterated chloroform;

[0032] Figure 6 This is the carbon nuclear magnetic resonance spectrum of the near-infrared second-zone iridium complex 2Fppy-oiC8-N^N with aggregation-induced emission properties prepared in Example 2 of the present invention in deuterated chloroform;

[0033] Figure 7 This is the hydrogen nuclear magnetic resonance spectrum of the near-infrared second-zone iridium complex ppy-miC8-N^N with aggregation-induced emission properties prepared in Example 3 of the present invention in deuterated chloroform;

[0034] Figure 8 This is the carbon nuclear magnetic resonance spectrum of the near-infrared second-zone iridium complex ppy-miC8-N^N with aggregation-induced emission properties prepared in Example 3 of the present invention in deuterated chloroform;

[0035] Fig. 9 This is the nuclear magnetic resonance hydrogen spectrum of the near-infrared second-region iridium complex 2Fppy-miC8-N^N with aggregation-induced emission properties prepared in Example 4 of the present invention in deuterated chloroform;

[0036] Fig.10 This is the nuclear magnetic resonance fluorine spectrum of the near-infrared second-zone iridium complex 2Fppy-miC8-N^N with aggregation-induced emission properties prepared in Example 4 of the present invention in deuterated chloroform;

[0037] Fig.11 This is the carbon nuclear magnetic resonance spectrum of the near-infrared second-zone iridium complex 2Fppy-miC8-N^N with aggregation-induced emission properties prepared in Example 4 of the present invention in deuterated chloroform;

[0038] Fig.12 is an ultraviolet absorption spectrum of the near-infrared second-region iridium complex with aggregation-induced emission properties prepared in Examples 1, 2, 3 and 4 of the present invention in tetrahydrofuran;

[0039] Fig.13 It is a fluorescence emission spectrum of the near-infrared second-region iridium complexes with aggregation-induced emission properties in tetrahydrofuran according to Examples 1, 2, 3 and 4 of the present invention;

[0040] Fig.14 is an aggregation-induced luminescence curve of the near-infrared second-region iridium complex with aggregation-induced luminescence properties prepared in Example 1 of the present invention in tetrahydrofuran / water;

[0041] Fig.15 is an aggregation-induced luminescence curve of the near-infrared second-region iridium complex with aggregation-induced luminescence properties prepared in Example 2 of the present invention in tetrahydrofuran / water;

[0042] Fig.16 This is a photothermal conversion efficiency diagram of nanoparticles ppy-oiC8-N^N NPs prepared from the near-infrared second-zone iridium complex with aggregation-induced emission properties in Example 1 of the present invention under 808nm laser irradiation;

[0043] Fig.17is a graph of the ROS generating ability of the nanoparticles ppy-oiC8-N^N NPs prepared in Example 5 of the present invention;

[0044] Fig.18 This is an experimental diagram of the dark toxicity and photothermal-photodynamic synergistic killing effect of the nanoparticles ppy-oiC8-N^N NPs prepared in Example 5 of the present invention on 4T1 cells;

[0045] Fig.19 This is a fluorescence / photoacoustic / photothermal synergistic imaging effect diagram of the nanoparticles ppy-oiC8-N^N NPs prepared in Example 5 of the present invention on breast cancer;

[0046] Fig. 20 This is a diagram showing the photothermal-photodynamic synergistic treatment effect of breast cancer using nanoparticles ppy-oiC8-N^N NPs prepared from the near-infrared second-zone iridium complex with aggregation-induced emission properties in Example 1 of the present invention. DETAILED DESCRIPTION

[0047] The present invention provides a near-infrared second-zone iridium complex with aggregation-induced luminescence properties and a preparation method and application thereof. In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0048] The present invention provides a near-infrared second-zone iridium complex with aggregation-induced luminescence properties, the structural formula of which is shown below:

[0049]

[0050] Wherein, R1 is selected from one of S and Se, R2 and R3 are independently selected from H and R4 is selected from one of H and F.

[0051] In this embodiment, the molecular structure of the near-infrared II region iridium complex with aggregation-induced emission properties is a DAD-type N^N ligand with dipyrido[3,2-a:2',3'-c][1,2,5]thiadiazo[3,4-i]phenazine as an acceptor (A), triphenylamine as a donor (D), and an iridium complex thereof. The large conjugated rigid acceptor and the DAD structure can ensure that the molecule has a lower energy gap, so that it has near-infrared II region (NIR-II) emission, and the propeller-type triphenylamine and the ortho-alkyl-substituted thiophene π-bridge can effectively inhibit the aggregation of the molecule, so that it has aggregation-induced emission properties. At the same time, the electron-withdrawing iridium ion coordination further improves the electron-withdrawing ability of the acceptor, and the absorption and emission of the molecule as a whole are red-shifted.

[0052] The embodiment of the present invention provides a method for preparing a near-infrared second-region iridium complex having aggregation-induced emission properties, characterized in that the preparation method comprises the following steps:

[0053] Under a protective atmosphere, formula I and formula II are added to a solvent, and a first stirring treatment is performed, and then an ion exchanger is added, and a second stirring treatment is performed to obtain a near-infrared second-zone iridium complex having aggregation-induced emission properties and a structural formula as shown in formula III;

[0054] The above reaction route is as follows:

[0055]

[0056] In some embodiments, the molar ratio of Formula I to Formula II is 1.5-2.5:1.

[0057] In the embodiment of the present invention, the molar ratio of Formula I to Formula II is controlled at 1.5 to 2.5:1. A higher molar ratio will cause a waste of raw materials, while a lower molar ratio will result in an incomplete reaction, thereby improving the utilization rate of raw materials.

[0058] In some preferred embodiments, the molar ratio of Formula I to Formula II is 2:1.

[0059] In some embodiments, the solvent is a mixed solvent including dichloromethane and methanol, and the volume ratio of dichloromethane to methanol is 3:1.

[0060] In some embodiments, the molar ratio of the ion exchanger to Formula I is 1 to 2:1.

[0061] In the embodiment of the present invention, the molar ratio of the ion exchanger to formula I is 1 to 2:1. More will cause a waste of raw materials, and less will result in insufficient reaction, thereby improving the utilization rate of raw materials.

[0062] In some preferred embodiments, the molar ratio of the ion exchanger to formula I is 1.5:1.

[0063] In some embodiments, the ion exchanger is potassium hexafluorophosphate or potassium tetrafluoroborate.

[0064] In some embodiments, the first stirring treatment is specifically: stirring at 40-60° C. for 12-18 hours in dark conditions; the second stirring treatment is specifically: stirring at room temperature for 4-6 hours.

[0065] In some preferred embodiments, the first stirring treatment is specifically: stirring at 40° C. for 12 hours in the dark; and the second stirring treatment is specifically: stirring at room temperature for 4 hours.

[0066] In some embodiments, after the second stirring process is performed, the method further comprises the following steps:

[0067] After the mixed solvent is evaporated, a purification treatment is performed to obtain the near-infrared second-zone iridium complex with aggregation-induced luminescence properties.

[0068] In some embodiments, the preparation of formula I comprises the following steps:

[0069] Equimolar amounts of Formula IV and 1,10-phenanthroline-5,6-dione were added to a mixed solvent of chloroform and acetic acid (volume ratio of 1:1), and the reaction was stirred at 80°C for 24 hours; after the reaction was completed, the reaction mixture was cooled to room temperature and extracted three times with dichloromethane. The organic layer was then dried over anhydrous Na2SO4 and concentrated in vacuo to obtain a crude product. The crude product was purified by column chromatography using petroleum ether and dichloromethane as eluents to obtain the formula I. The route diagram of the above reaction is as follows:

[0070]

[0071] Wherein, R1 is independently selected from one of S and Se, R2 and R3 are independently selected from H and One of them.

[0072] In some embodiments, the preparation of formula IV comprises the following steps:

[0073] Under N2 atmosphere, add formula VI and Fe (molar ratio of 1:12) to acetic acid solvent, and stir the reaction at 80°C for 12 hours. After the reaction is completed, cool to room temperature and add water, and a large amount of yellow solid precipitates in the solution. The yellow solid is filtered, washed with water, then redissolved and extracted with dichloromethane and dried by rotation, and finally the product is precipitated with methanol, the yellow solid is filtered and vacuum dried to obtain a yellow powder product IV. The route diagram of the above reaction is as follows:

[0074]

[0075] Wherein, R1 is independently selected from one of S and Se, R2 and R3 are independently selected from H and One of them.

[0076] In some embodiments, the preparation of formula VI comprises the following steps:

[0077] Under N2 atmosphere, Formula VII, Formula VIII and bistriphenylphosphine palladium dichloride (molar ratio of 5:10:2) were added to toluene solvent and stirred at 110°C for 12 hours. After the reaction was completed, silica gel column was used for separation, dichloromethane and petroleum ether were used as eluents, and the separated blue-purple solution was collected, dried by spin drying, and washed with methanol to obtain a dark brown solid Formula VI. The route diagram of the above reaction is as follows:

[0078]

[0079] Wherein, R1 is independently selected from one of S and Se, R2 and R3 are independently selected from H and One of them.

[0080] In some embodiments, the preparation of the compound of formula VIII comprises the following steps:

[0081] Under N2 atmosphere, add formula IX, n-butyl lithium and tributyltin chloride (molar ratio of 1:1:1) to tetrahydrofuran solvent, stir and react at -78°C for 12 hours to obtain a brownish brown color, add water to quench the reaction and spin dry. Then extract with dichloromethane, wash with water, spin dry and dry. Obtain brownish brown viscous formula VIII. The route diagram of the above reaction is as follows:

[0082]

[0083] Wherein, R2 and R3 are independently selected from H and One of them.

[0084] In some embodiments, the preparation of formula IX comprises the following steps:

[0085] Under N2 atmosphere, 4-bromotriphenylamine, formula X and tributyltin chloride (molar ratio of 1:1:1) were added to toluene solvent and stirred at 110°C for 12 hours. After the reaction was completed, silica gel column was used for separation, dichloromethane and petroleum ether were used as eluents, and colorless viscous substances were collected and dried to obtain formula IX. The route diagram of the above reaction is as follows:

[0086]

[0087] Wherein, R2 and R3 are independently selected from H and One of them.

[0088] In one embodiment, the preparation of formula II comprises the following steps:

[0089] Under N2 atmosphere, Formula V and iridium chloride hydrate (molar ratio of 1:2) were added to a mixed solvent of 2-methoxyethanol and water (volume ratio of 3:1), and stirred at 115°C for 18 hours. After the reaction was completed, it was cooled to room temperature and water was added thereto, and a large amount of yellow-green solid precipitated from the solution. The yellow-green solid was filtered, washed with water, petroleum ether and n-hexane in sequence, and then vacuum dried to obtain a yellow-green powder product of Formula II. The route diagram of the above reaction is as follows:

[0090]

[0091] Wherein, R4 is independently selected from one of H and F.

[0092] The present invention also provides a nanoparticle, the preparation of which comprises the following steps:

[0093] A tetrahydrofuran solution of a near-infrared second region iridium complex having aggregation-induced emission properties is mixed with distearoylphosphatidylethanolamine-polyethylene glycol 2000. Subsequently, an ultrasonic stirring treatment is performed for 2 minutes using an ultrasonic instrument. After the ultrasonic stirring treatment, the resulting mixture is placed in a dialysis bag and dialyzed in ultrapure water for 24 hours. Finally, the obtained nanoparticles are concentrated by ultrafiltration.

[0094] In some embodiments, the use of the above-mentioned near-infrared second-zone iridium complex with aggregation-induced emission properties or the above-mentioned nanoparticles in the preparation of multimodal integrated diagnosis and treatment reagents is provided.

[0095] In some embodiments, the multimodal diagnostic and therapeutic integrated reagent is used to treat cancer.

[0096] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments, and are only used to illustrate the present invention but not to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0097] Example 1

[0098] A preparation method of a near-infrared second-zone iridium complex having aggregation-induced emission properties comprises the following steps:

[0099] Under N2 atmosphere, 200 mg of Formula I (wherein R1 is S, R2 is R3 is H) and 97 mg of formula II (wherein R4 is H) are added to 24 mL of a mixed solvent of dichloromethane and methanol (the volume ratio of dichloromethane to methanol is 3:1), and the reaction is stirred at 40°C for 12 hours under dark conditions. After the reaction is completed, 200 mg of potassium hexafluorophosphate is added, and the resulting mixture is stirred for another 4 hours at room temperature. After the mixed solvent is completely evaporated, it is purified by column chromatography using dichloromethane and methanol (the volume ratio of dichloromethane to methanol is 80:1) as eluents to obtain 240 mg of a black solid formula III (referred to as ppy-oiC8-N^N) with a yield of 83%.

[0100] Example 2

[0101] A preparation method of a near-infrared second-zone iridium complex having aggregation-induced emission properties comprises the following steps:

[0102] Under N2 atmosphere, 200 mg of Formula I (wherein R1 is S, R2 is R3 is H) and 110.03 mg of formula II (wherein R4 is F) are added to 24 mL of a mixed solvent of dichloromethane and methanol (the volume ratio of dichloromethane to methanol is 3:1), and the reaction is stirred at 40°C for 12 hours under dark conditions. After the reaction is completed, 200 mg of potassium hexafluorophosphate is added, and the resulting mixture is stirred for another 4 hours at room temperature. After the mixed solvent is completely evaporated, dichloromethane and methanol (the volume ratio of dichloromethane to methanol is 100:1) are used as eluents for purification by column chromatography to obtain 290 mg of a black solid formula III (recorded as 2Fppy-oiC8-N^N), with a yield of 83%.

[0103] Example 3

[0104] A preparation method of a near-infrared second-zone iridium complex having aggregation-induced emission properties comprises the following steps:

[0105] Under N2 atmosphere, 100 mg of Formula I (wherein R1 is S, R2 is H, and R3 is ) and 48.51 mg of formula II (wherein R4 is H) were added to 12 mL of a mixed solvent of dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 3:1), and the reaction was stirred at 40°C for 12 hours under dark conditions. After the reaction was completed, 300 mg of potassium hexafluorophosphate was added, and the resulting mixture was stirred for another 4 hours at room temperature. After the mixed solvent was completely evaporated, it was purified by column chromatography using dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 50:1) as eluents to obtain 126 mg of a black solid formula III (referred to as ppy-miC8-N^N) with a yield of 80%.

[0106] Example 4

[0107] A preparation method of a near-infrared second-zone iridium complex having aggregation-induced emission properties comprises the following steps:

[0108] Under N2 atmosphere, 200 mg of Formula I (wherein R1 is S, R2 is H, and R3 is ) and 110.03 mg of formula II (wherein R4 is F) were added to 24 mL of a mixed solvent of dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 3:1), and the reaction was stirred at 40°C for 12 hours under dark conditions. After the reaction was completed, 300 mg of potassium hexafluorophosphate was added, and the resulting mixture was stirred for another 4 hours at room temperature. After the mixed solvent was completely evaporated, it was purified by column chromatography using dichloromethane and methanol (the volume ratio of dichloromethane to methanol was 100:1) as eluents to obtain 270 mg of a black solid formula III (referred to as 2Fppy-miC8-N^N) with a yield of 83%.

[0109] The synthetic route of the near-infrared second-region iridium complexes (ppy-oiC8-N^N, 2Fppy-oiC8-N^N, ppy-miC8-N^N, 2Fppy-miC8-N^N) prepared in the above Examples 1-4 with aggregation-induced emission properties is as follows Figure 1 shown.

[0110] The H NMR spectrum and C NMR spectrum of ppy-oiC8-N^N in deuterated chloroform are as follows Figure 2 and Figure 3 shown.

[0111] The hydrogen, fluorine and carbon NMR spectra of 2Fppy-oiC8-N^N in deuterated chloroform are as follows: Figure 4 , Figure 5 and Figure 6 shown.

[0112] The H NMR spectrum and C NMR spectrum of ppy-miC8-N^N in deuterated chloroform are shown in Figure 7 and Figure 8 shown.

[0113] The H NMR spectrum, F NMR spectrum and C NMR spectrum of 2Fppy-miC8-N^N in deuterated chloroform are shown in Fig. 9 , Fig.10 and Fig.11 shown.

[0114] Performance testing

[0115] The ultraviolet absorption spectra of ppy-oiC8-N^N in Example 1, 2Fppy-oiC8-N^N in Example 2, ppy-miC8-N^N in Example 3 and 2Fppy-miC8-N^N in Example 4 in tetrahydrofuran are shown in FIG. Fig.12 shown.

[0116] The fluorescence emission spectra of ppy-oiC8-N^N in Example 1, 2Fppy-oiC8-N^N in Example 2, ppy-miC8-N^N in Example 3 and 2Fppy-miC8-N^N in Example 4 in tetrahydrofuran are shown in the figure below: Fig.13 As shown, the emission wavelengths of the molecules in the four embodiments are all located in the second near-infrared region (greater than 1000 nm).

[0117] The fluorescence emission spectra of ppy-oiC8-N^N in Example 1 and 2Fppy-oiC8-N^N in Example 2 in a mixed solvent of tetrahydrofuran and water (the volume content of water in the mixed solvent is 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%, respectively) are shown in the figure below: Fig.14 and Fig.15 As shown, where I represents the luminescence intensity in a solution with a certain water content, and I0 represents the luminescence intensity in pure tetrahydrofuran, it can be seen that ppy-oiC8-N^N and 2Fppy-oiC8-N^N have the property of aggregation-induced emission and are aggregation-induced emission materials.

[0118] Example 5

[0119] A method for preparing nanoparticles comprises the following steps:

[0120] The tetrahydrofuran solution of ppy-oiC8-N^N prepared in Example 1 (ppy-oiC8-N^N is 1 mg, tetrahydrofuran is 1 mL) is mixed with distearoylphosphatidylethanolamine-polyethylene glycol 2000 (distearoylphosphatidylethanolamine is 10 mg, polyethylene glycol 2000 is 9 mL). Subsequently, ultrasonic stirring treatment is performed for 2 minutes using an ultrasonic instrument. After ultrasonic stirring treatment, the resulting mixture is placed in a dialysis bag and dialyzed in ultrapure water for 24 hours. Finally, nanoparticles (referred to as ppy-oiC8-N^N NPs) are obtained by ultrafiltration concentration.

[0121] Performance testing:

[0122] (1) The photothermal conversion efficiency of ppy-oiC8-N^N NPs (100 μM) prepared in Example 5 under 808 nm laser irradiation was tested. The results are as follows: Fig.16 As shown, its photothermal conversion efficiency is 60.5%, indicating that it has excellent photothermal conversion ability, where θ represents the ratio of the temperature change (ΔT) to the maximum temperature change (ΔTmax).

[0123] (2) Testing the ROS generation ability of the ppy-oiC8-N^N NPs prepared in Example 5 under 808 nm laser irradiation, the specific steps are as follows:

[0124] 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) was used as a ROS indicator to detect the ROS production of ppy-oiC8-N^N NPs in solution under irradiation with 808 nm laser (0.8 W cm-2).

[0125] First, the ethanol solution of DCFH-DA (1 mM DCFH-DA, 0.5 mL ethanol) was added to 2 mL NaOH solution (0.01 M) and stirred at room temperature for 30 minutes to hydrolyze DCFH-DA to DCFH. Then, the hydrolyzate was neutralized with 10 mL 1×PBS at pH 7.4 to obtain an activated ROS indicator (40 μM, 12.5 mL), which was stored at 4 ° C in the dark for later use. Then, the activated ROS indicator (40 μM) was mixed with ppy-oiC8-N^N NPs in PBS so that the final concentrations of the ROS indicator and ppy-oiC8-N^N NPs were both 1 μM. After 808 laser irradiation for different times, the fluorescence intensity of DCFH triggered by ROS generated by ppy-oiC8-N^N NPs was detected by fluorescence spectrometer to reflect the ROS generation. The excitation wavelength was 488 nm, and the fluorescence signals in the range of 490-600 nm were collected.

[0126] The results are as follows Fig.17 As shown in the figure, the fluorescence intensity of DCFH after 808 nm laser irradiation for 10 minutes was enhanced by nearly 250 times, indicating that it has a good ROS generation ability, where I represents the fluorescence intensity of DCFH triggered by ROS generated by ppy-oiC8-N^N NPs, and I0 represents the fluorescence intensity of DCFH without light.

[0127] (3) The dark toxicity and photothermal killing effects of the ppy-oiC8-N^N NPs prepared in Example 5 (with concentrations of 0 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, and 100 μM, respectively) on 4T1 cells were tested. The specific steps are as follows:

[0128] 4T1 cells were seeded in 96-well plates with an initial density of 5×103 cells / well and incubated for 24 hours. 4T1 cells were then treated with different concentrations of ppy-oiC8-N^N NPs. After 12 hours of incubation, 4T1 cells were directly exposed to 808nm laser (0.8W·cm-2) and irradiated for 5 minutes. At the same time, 4T1 cells without laser irradiation were used for dark toxicity assay. Subsequently, the cells were further cultured for 12 hours before the addition of CCK-8. Finally, cell viability was recorded using a microplate reader with a detection wavelength of 450nm.

[0129] The results are as follows Fig.18 As shown, the results are expressed as the survival percentage of 4T1 cells after various treatments relative to control 4T1 cells without any treatment. ppy-oiC8-N^N NPs still have low dark cytotoxicity in the range of 100μM and have excellent photothermal killing ability of 4T1 cells.

[0130] (4) The experiment of synergistic imaging (fluorescence / photoacoustic / photothermal, NIR-II FLI / PAI / PTI) of breast cancer by ppy-oiC8-N^N NPs prepared in Example 5 specifically includes the following steps:

[0131] After 4T1 tumor-bearing mice were injected with ppy-oiC8-N^N NPs (200 μL, 1.5 mM), fluorescence / photoacoustic imaging was performed on the mice at 0 h, 1 h, 3 h, 24 h, 36 h, and 48 h to detect the fluorescence / photoacoustic signals of the mouse tumors. The results are shown in Figure 2. Fig.19 As shown, ppy-oiC8-N^N NPs tended to be enriched in the tumor site of mice and reached a peak at 36h.

[0132] After fluorescence / photoacoustic imaging of 4T1 tumor-bearing mice, thermal imaging of the tumor site of mice was performed 36 h after injection of ppy-oiC8-N^N NPs (200 μL, 1.5 mM). Fig.19 As shown, under 808nm laser irradiation, the temperature of the mouse tumor site gradually increased.

[0133] Therefore, ppy-oiC8-N^N NPs have excellent specific imaging and therapeutic capabilities for tumors.

[0134] (5) The ppy-oiC8-N^N NPs prepared in Example 5 were used for the synergistic photothermal / photodynamic treatment of breast cancer, specifically comprising the following steps:

[0135] The 4T1 tumor-bearing mice were randomly divided into 4 groups (n=5 in each group) for different treatments, named "PBS" group, "PBS+L" group, "ppy-oiC8-N^N NPs" group and "ppy-oiC8-N^N NPs+L" group, respectively.

[0136] For the “PBS+L” group, mice were injected with PBS (200 μL) via the tail vein on day 0 and exposed to 808 nm laser (0.8 W cm-2) for 10 min at 36 h after injection;

[0137] For the “PBS” group, mice were injected with PBS (200 μL) via the tail vein on day 0 without light exposure, serving as the control group for the “PBS+L” group;

[0138] For the “ppy-oiC8-N^N NPs+L” group, mice were injected with ppy-oiC8-N^N NPs (200 μL, 1.5 mM) via the tail vein on day 0 and exposed to 808 nm laser (0.8 W cm-2) for 10 min at 36 h after injection;

[0139] For the “ppy-oiC8-N^N NPs” group, mice were injected with ppy-oiC8-N^N NPs (200 μL, 1.5 mM) via the tail vein on day 0 without light exposure, serving as the control group for the “ppy-oiC8-N^N NPs+L” group;

[0140] The tumor volume of mice was recorded every 3 days during the treatment and calculated as V=a×b2 / 2. (a: tumor length; b: tumor width). The relative tumor volume (RTV) was calculated as RTV=V / V0, where V0 is the initial tumor volume.

[0141] The results are as follows Fig.19 and Fig. 20 As shown, it can be seen that ppy-oiC8-N^N NPs can effectively perform photothermal / photodynamic therapy on breast cancer tumors. After the third day, the tumors in the treatment group "ppy-oiC8-N^N NPs+L" group completely disappeared.

[0142] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A near-infrared second-region iridium complex with aggregation-induced emission properties, characterized in that: Its structural formula is as follows: Wherein, R1 is selected from one of S and Se, R2 and R3 are independently selected from H and R4 is selected from one of H and F.

2. A method for preparing a near-infrared second-region iridium complex having aggregation-induced emission properties as claimed in claim 1, characterized in that: The preparation method comprises the following steps: Under a protective atmosphere, formula I and formula II are added to a solvent, and a first stirring treatment is performed, and then an ion exchanger is added, and a second stirring treatment is performed to obtain a near-infrared second-zone iridium complex having aggregation-induced emission properties and a structural formula as shown in formula III; The above reaction route is as follows:

3. The method for preparing the near-infrared second-region iridium complex with aggregation-induced emission properties according to claim 2, characterized in that: The molar ratio of formula I to formula II is (1.5-2.5):

1.

4. The method for preparing the near-infrared second-region iridium complex with aggregation-induced emission properties according to claim 2, characterized in that: The solvent is a mixed solvent including dichloromethane and methanol.

5. The method for preparing the near-infrared second-region iridium complex with aggregation-induced emission properties according to claim 2, characterized in that: The molar ratio of the ion exchanger to formula I is (1-2):

1.

6. The method for preparing the near-infrared second-region iridium complex with aggregation-induced emission properties according to claim 2, characterized in that: The ion exchanger is potassium hexafluorophosphate or potassium tetrafluoroborate.

7. The method for preparing the near-infrared second-region iridium complex with aggregation-induced emission properties according to claim 2, characterized in that: The first stirring treatment specifically comprises: stirring at 40 to 60° C. for 12 to 18 hours in dark conditions; The second stirring treatment specifically comprises: stirring at room temperature for 4 to 6 hours.

8. The method for preparing the near-infrared second-region iridium complex with aggregation-induced emission properties according to claim 2, characterized in that: After the second stirring process, the method further comprises the following steps: After the mixed solvent is evaporated, a purification treatment is performed to obtain the near-infrared second-zone iridium complex with aggregation-induced luminescence properties.

9. Use of the near-infrared second-zone iridium complex with aggregation-induced emission properties as described in claim 1 in the preparation of multimodal integrated diagnosis and treatment reagents.

10. The use according to claim 9, characterized in that The multimodal integrated diagnosis and treatment reagent is used to treat cancer.

Citation Information

Patent Citations

  • D-A-D cyclometalated iridium complex near-infrared luminous material based on aryl quinoxaline and application

    CN109134550A

  • Aggregation-induced luminescent and piezochromism luminescent near-infrared ion-type iridium (III) complex and application thereof

    CN109232661A

Cited By

  • Near-infrared light excited iridium (III) complex photosensitizer as well as preparation method and application thereof

    CN118930586A

  • A type of near-infrared light-excited iridium (III) complex photosensitizer, preparation method and application

    CN118930586B

  • Near-infrared two-region aggregation-induced emission probe, nanoparticle, and preparation method and application of near-infrared two-region aggregation-induced emission probe and nanoparticle

    CN121342846A